Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2024-05-08 Interim / Quarterly Rep…
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis Q1 Unaudited Condensed Consolidated Interim Financial Statements.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Consolidated Interim Financial Statements' for Oculis Holding AG. It contains detailed financial tables including the Statement of Financial Position, Statement of Loss, Statement of Comprehensive Loss, Statement of Changes in Equity, and Statement of Cash Flows for the three-month period ended March 31, 2024. It also includes extensive notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. Q1 2024
2024-05-08 English
Oculis Q1 MDA.pdf
Management Reports Classification · 100% confidence The document is titled 'MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS' and is filed as an exhibit (Exhibit 99.2) to a Form 6-K. It provides a detailed narrative explanation of the company's financial performance, business trends, and operational outlook for the three months ended March 31, 2024. This content aligns perfectly with the definition of a Management's Discussion and Analysis (MDA) report.
2024-05-08 English
Oculis Q1 2024 earning Press Release.pdf
Earnings Release Classification · 100% confidence The document is a press release titled 'Oculis Reports Q1 2024 Financial Results and Provides Company Updates'. It contains key financial highlights, clinical trial progress, and condensed financial statements (balance sheet, income statement, and non-IFRS reconciliations) for the three-month period ended March 31, 2024. While it contains financial data, it is structured as an initial announcement of quarterly results rather than a full, comprehensive interim report. Therefore, it is classified as an Earnings Release (ER). Q1 2024
2024-05-08 English
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
Earnings Release Classification · 100% confidence The document is a press release titled 'Oculis Reports Q1 2024 Financial Results and Provides Company Updates'. It contains key financial highlights, operational updates, and condensed financial statements for the three-month period ended March 31, 2024. While it includes financial data, it is structured as an initial announcement of quarterly results rather than a full, comprehensive interim report. According to the filing definitions, an 'Earnings Release' (ER) is the initial announcement of quarterly/periodical financial results, which matches this document perfectly. Q1 2024
2024-05-08 English
Oculis Publishes Invitation to the Annual General Meeting
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) informing shareholders that the invitation and materials for the 2024 Annual General Meeting have been published on the company's website. It does not contain the actual proxy materials or the meeting presentation itself, but rather serves as a notification of their availability. Therefore, it falls under the Report Publication Announcement (RPA) category.
2024-05-07 English
6-K
Regulatory Filings
2024-04-29 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.